Treatment

To help achieve desired results, patients should complete all three treatment sessions1

Adult woman’s buttocks before QWO treatment
A timeline for treatments highlighting days 1, 22, and 43
A timeline for treatments highlighting days 1, 22, and 43

Treatment Administration

Patients may receive up to 12 injections per buttock, for a maximum of 24 injections for both buttocks.1

Some dimples may require more than one injection.3,11

Injection Technique

This injection technique is intended for use on the buttocks only1

  1. Position the needle at a 90° angle to the patient’s skin surface and inject one 0.1 mL aliquot into the dimple.
  2. Withdraw the needle slightly without removing it from the injection site and reposition the needle at a ~45° angle toward the patient’s head. Inject a second 0.1 mL aliquot.
  3. Again, withdraw the needle slightly and reposition the needle at a ~45° angle toward the patient’s feet. Inject the third 0.1 mL aliquot.
Graphic using syringe and concave half circle to demonstrate injection technique.
Graphic using syringe and concave half circle to demonstrate injection technique.

QWO is supplied as a sterile, preservative-free lyophilized powder in a single-use vial that must be reconstituted before use.1

0.92 mg vial
0.92 mg QWO vial and 4 mL diluent.
4 mL diluent
Up to 12 Injections*

or

1.84 mg vial
1.84 mg QWO vial and 8 mL diluent.
8 mL diluent
Up to 24 Injections*

*There is a maximum up to 12 injections per buttock.

Coworkers viewing computer screen.

Clinical Education Center

Looking for more information?
Visit our Clinical Education Center for publications, presentations and video content to help educate you on the science and data behind QWO.

What to expect with QWO

Learn more about the safety of QWO and what your patients should expect post-treatment.

Indication

Qwo® is indicated for the treatment of moderate to severe cellulite in the buttocks of adult women.

Important Safety Information for QWO

Contraindications

QWO is contraindicated in patients with a history of hypersensitivity to collagenase or to any of the excipients or the presence of infection at the injection sites.

Warnings and Precautions

Hypersensitivity Reactions

Serious hypersensitivity reactions including anaphylaxis have been reported with the use of collagenase clostridium histolyticum. If such a reaction occurs, further injection of QWO should be discontinued and appropriate medical therapy immediately instituted. Advise patients to seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions.

Injection Site Bruising

In clinical trials, 84% of subjects treated with QWO experienced injection site bruising. Subjects with coagulation disorders or using anticoagulant or antiplatelet medications (except those taking ≤150 mg aspirin daily) were excluded from participating in Trials 1 and 2.

QWO should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet (except those taking ≤150 mg aspirin daily) or anticoagulant therapy.

Substitution of Collagenase Products

QWO must not be substituted with other injectable collagenase products.

QWO is not intended for the treatment of Peyronie’s Disease or Dupuytren’s Contracture.

Adverse Reactions

In clinical trials, the most commonly reported adverse reactions in patients treated with QWO with an incidence ≥ 10% were at the injection site: bruising, pain, nodule and pruritus.

View Full Prescribing Information for QWO.